Unichem gets USFDA nod for Zonisamide Capsules

Zonisamide Capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

78
USFDA
Picture: Pixabay

Last Updated on January 29, 2021 by The Health Master

Unichem Laboratories has received ANDA approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from the United States Food and Drug Administration (USFDA).

This drug is to market a generic version of Zonegran (Zonisamide) Capsules of Sunovion Pharmaceuticals.

Zonisamide Capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

The product will be commercialised from Unichem’s Goa plant.


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading